LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Back to previous search Search history
Advanced search

Your last searches

  1. AU="Marina Paola Gardiman"
  2. AU="Labarthe, Simon"
  3. AU="Jiahui Li"
  4. AU="Geier, Johannes"
  5. AU=Thangaraju Pugazhenthan
  6. AU="Tapio, Joona"
  7. AU="Navaratnam, Dhasakumar"
  8. AU="Blank, Marissa Cathleen"
  9. AU="Sadeghi, Yasaman"
  10. AU=Ye Keqiang
  11. AU="Huda, Walter"
  12. AU="Petrova, Polina E"
  13. AU="Pond, Gregory"
  14. AU=Krzewski Konrad
  15. AU="Feng, Yuquan"
  16. AU="Schmermund, Ben Niklas"
  17. AU="Soni, Payal D"
  18. AU="Romero-García, Carolina"
  19. AU="Petty, Lloyd"
  20. AU="James E. Posey"

Search results

Result 1 - 2 of total 2

Search options

  1. Article ; Online: The role of radiation therapy and systemic treatments in meningioma

    Mario Caccese / Fabio Busato / Angela Guerriero / Marta Padovan / Giulia Cerretti / Marina Paola Gardiman / Vittorina Zagonel / Giuseppe Lombardi

    Cancer Medicine, Vol 12, Iss 15, Pp 16041-

    The present and the future

    2023  Volume 16053

    Abstract: Abstract Meningiomas are the most prevalent tumors of the central nervous system. Their standard treatment is surgery, which can be curative. Adjuvant radiotherapy treatment is reserved for newly diagnosed cases of grade II and grade III meningiomas in ... ...

    Abstract Abstract Meningiomas are the most prevalent tumors of the central nervous system. Their standard treatment is surgery, which can be curative. Adjuvant radiotherapy treatment is reserved for newly diagnosed cases of grade II and grade III meningiomas in cases of recurrent disease or when surgery is not radical or feasible. However, around 20% of these patients cannot undergo further surgical and/or radiotherapy treatment. Systemic oncological therapy can find its place in this setting. Several tyrosine kinase inhibitors have been tested (gefitinib, erlotinib, sunitinib) with unsatisfactory or negative results. Bevacizumab has shown encouraging results in these settings of patients. Immunotherapy with immune checkpoint inhibitors has reported interesting results with modest objective response rates. Several ongoing studies are assessing different target therapies and multimodal therapies; the results are to be disclosed. Not only a better understanding of the molecular characteristics in meningiomas has allowed the gathering of more information regarding pathogenesis and prognosis, but in addition, the availability of new target therapy, immunotherapy, and biological drugs has widened the scope of potentially effective treatments in this patient population. The aim of this review was to explore the radiotherapy and systemic treatments of meningioma with an analysis of ongoing trials and future therapeutic perspectives.
    Keywords meningioma ; new drugs ; precision medicine ; systemic treatment ; Neoplasms. Tumors. Oncology. Including cancer and carcinogens ; RC254-282
    Subject code 616
    Language English
    Publishing date 2023-08-01T00:00:00Z
    Publisher Wiley
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  2. Article ; Online: NSD1 Mutations and Pediatric High-Grade Gliomas

    Antonio d’Amati / Arianna Nicolussi / Evelina Miele / Angela Mastronuzzi / Sabrina Rossi / Francesca Gianno / Francesca Romana Buttarelli / Simone Minasi / Pietro Lodeserto / Marina Paola Gardiman / Elisabetta Viscardi / Anna Coppa / Vittoria Donofrio / Isabella Giovannoni / Felice Giangaspero / Manila Antonelli

    Diagnostics, Vol 13, Iss 1, p

    A Comparative Genomic Study in Primary and Recurrent Tumors

    2022  Volume 78

    Abstract: Pediatric high-grade gliomas represent a heterogeneous group of tumors with a wide variety of molecular features. We performed whole exome sequencing and methylation profiling on matched primary and recurrent tumors from four pediatric patients with ... ...

    Abstract Pediatric high-grade gliomas represent a heterogeneous group of tumors with a wide variety of molecular features. We performed whole exome sequencing and methylation profiling on matched primary and recurrent tumors from four pediatric patients with hemispheric high-grade gliomas. Genetic analysis showed the presence of some variants shared between primary and recurrent tumors, along with other variants exclusive of primary or recurrent tumors. NSD1 variants, all novel and not previously reported, were present at high frequency in our series (100%) and were all shared between the samples, independently of primary or recurrence. For every variant, in silico prediction tools estimated a high probability of altering protein function. The novel NSD1 variant (c.5924T > A; p.Leu1975His) was present in one in four cases at recurrence, and in two in four cases at primary. The novel NSD1 variant (c.5993T > A; p.Met1998Lys) was present in one in four cases both at primary and recurrence, and in one in four cases only at primary. The presence of NSD1 mutations only at recurrence may suggest that they can be sub-clonal, while the presence in both primary and recurrence implies that they can also represent early and stable events. Furthermore, their presence only in primary, but not in recurrent tumors, suggest that NSD1 mutations may also be influenced by treatment.
    Keywords pediatric high-grade gliomas ; hemispheric pediatric high-grade gliomas ; high grade glioma H3-/IDH-wildtype ; glioma ; CNS tumors ; molecular biology ; Medicine (General) ; R5-920
    Language English
    Publishing date 2022-12-01T00:00:00Z
    Publisher MDPI AG
    Document type Article ; Online
    Database BASE - Bielefeld Academic Search Engine (life sciences selection)

    Full text online

    More links

    Kategorien

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

To top